Vor bio appoints accomplished oncology and cancer immunotherapy r&d executive, fouad namouni, m.d., to its board of directors

Cambridge, mass., may 02, 2024 (globe newswire) -- vor bio (nasdaq: vor), a clinical-stage cell and genome engineering company, today announced the appointment of fouad namouni, m.d., to its board of directors. dr. namouni currently serves as president of research & development at blueprint medicines, bringing a wealth of industry experience and expertise to vor bio's board.
VOR Ratings Summary
VOR Quant Ranking